Guggenheim Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $54

Benzinga Newsdesk www.benzinga.com Neutral 65.9%

Neg 0% Neu 65.9% Pos 0%

Guggenheim analyst Brad Canino initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Buy rating and announces Price Target of $54.